Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13490
UPID:
BIRC2_HUMAN
Alternative names:
Cellular inhibitor of apoptosis 1; IAP homolog B; Inhibitor of apoptosis protein 2; RING finger protein 48; RING-type E3 ubiquitin transferase BIRC2; TNFR2-TRAF-signaling complex protein 2
Alternative UPACC:
Q13490; B4E026; Q16516; Q4TTG0
Background:
Baculoviral IAP repeat-containing protein 2, known by names such as Cellular inhibitor of apoptosis 1 and RING-type E3 ubiquitin transferase BIRC2, plays a pivotal role in cellular processes. It regulates apoptosis, inflammation, cell proliferation, and invasion, acting as an E3 ubiquitin-protein ligase to modulate NF-kappa-B signaling. Its targets include RIPK1, CASP8, and TRAF2, among others, and it also influences innate immune signaling through pattern recognition receptors.
Therapeutic significance:
Understanding the role of Baculoviral IAP repeat-containing protein 2 could open doors to potential therapeutic strategies.